Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 19Terminated 3Unknown 2

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma 19Lymphoma, Large B-Cell, Diffuse 16Leukemia 11Lymphoma, Non-Hodgkin 10Burkitt Lymphoma 10Recurrence 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 6Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid, Acute 4Multiple Myeloma 3Medulloblastoma 3Lymphoma, T-Cell, Peripheral 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Sarcoma, Ewing 2Neuroblastoma 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphatic Diseases 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × Vincristine × Clear all
NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT00215943 2014-04-17

Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)

H. Lee Moffitt Cancer Center and Research Institute

Phase 3 Terminated
90 enrolled 10 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT00441168 2014-03-21

Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Janssen-Cilag International NV

Phase 2 Terminated
30 enrolled 14 charts
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡